Psychological Treatment of Comorbid Insomnia and Depression: A Double-Blind Randomized Placebo-Controlled Trial

被引:2
|
作者
Blom, Kerstin [1 ,2 ]
Forsell, Erik [1 ,2 ]
Hellberg, Monica [2 ]
Svanborg, Cecilia [1 ,2 ]
Jernelov, Susanna [1 ,2 ,3 ]
Kaldo, Viktor [1 ,2 ,4 ]
机构
[1] Karolinska Inst, Ctr Psychiat Res, Dept Clin Neurosci, Stockholm, Sweden
[2] Stockholm Hlth Care Serv, Stockholm, Sweden
[3] Karolinska Inst, Dept Clin Neurosci, Div Psychol, Stockholm, Sweden
[4] Linnaeus Univ, Fac Hlth & Life Sci, Dept Psychol, Vaxjo, Sweden
关键词
Insomnia; Depression; Comorbidity; Psychological treatment; Randomized controlled trial; COGNITIVE-BEHAVIORAL THERAPY; SLEEP RESTRICTION THERAPY; SELF-HELP; DSM-IV; MAJOR DEPRESSION; SOCIAL ANXIETY; FOLLOW-UP; CBT-I; METAANALYSIS; PHARMACOTHERAPY;
D O I
10.1159/000536063
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Introduction: Insomnia and depression are highly prevalent disorders and commonly occur together. Cognitive behavioral therapy for insomnia, CBT-I, has been shown to be effective in treating insomnia and also comorbid depression. However, it is unclear whether effects of CBT-I on depression are specific or nonspecific. Also, depressive symptoms often remain too high after CBT-I, indicating a need for improved treatments. The objective was to determine whether combining CBT-I with CBT for depression, without increasing treatment length, reduces both insomnia and depression more than CBT for depression with a placebo insomnia intervention. Methods: A 12-week double-blind randomized controlled trial with a 6-month follow-up in a psychiatric setting using therapist-guided internet-delivered treatments was conducted. Patients (N = 126) were diagnosed with insomnia disorder and major depression by physicians. Primary outcome measures were as follows: self-rating scales Insomnia Severity Index (ISI) and Montgomery-angstrom sberg Depression Rating Scale (MADRS-S). Results: The combined treatment showed specific effects on insomnia severity over the control treatment (p = 0.007) but was not more effective in reducing depression severity. Within-group effects (Cohen's d) at post and at 6 months were as follows: ISI 1.40 and 1.42 (combined treatment), 0.95 and 1.00 (control); MADRS-S 0.97 and 1.12 (combined), 0.88 and 0.89 (control). Conclusions: CBT-I shows large specific effects on insomnia severity and is superior to control in this regard. Both treatments had similar effects on depression severity, i.e., combining CBT-I with CBT for depression did not enhance outcomes on depression compared to control. We suggest CBT-I should always be offered to patients with insomnia and depression comorbidity, possibly as the first-hand choice. Combining it with a psychological treatment for depression could be too burdening and may not be beneficial.
引用
收藏
页码:100 / 113
页数:14
相关论文
共 50 条
  • [41] ORAL S-ADENOSYLMETHIONINE IN DEPRESSION - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    KAGAN, BL
    SULTZER, DL
    ROSENLICHT, N
    GERNER, RH
    AMERICAN JOURNAL OF PSYCHIATRY, 1990, 147 (05): : 591 - 595
  • [42] Treatment of snorers with a volatile oil -: A randomized, double-blind placebo-controlled trial
    Ulfberg, J
    Nyström, B
    ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES, 2001, 63 (05): : 298 - 301
  • [43] Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence
    Heinzerling, Keith G.
    Swanson, Aimee-Noelle
    Kim, Soeun
    Cederblom, Lisa
    Moe, Ardis
    Ling, Walter
    Shoptaw, Steven
    DRUG AND ALCOHOL DEPENDENCE, 2010, 109 (1-3) : 20 - 29
  • [44] Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial
    Coffin, Phillip Oliver
    Santos, Glenn-Milo
    Das, Moupali
    Santos, Deirdre M.
    Huffaker, Shannon
    Matheson, Tim
    Gasper, James
    Vittinghoff, Eric
    Colfax, Grant N.
    ADDICTION, 2013, 108 (04) : 751 - 761
  • [45] Gabapentin in the treatment of fibromyalgia - A randomized, double-blind, placebo-controlled, multicenter trial
    Arnold, Lesley M.
    Goldenberg, Don L.
    Stanford, Sharon B.
    Lalonde, Justine K.
    Sandhu, H. S.
    Keck, Paul E., Jr.
    Welge, Jeffrey A.
    Bishop, Fred
    Stanford, Kevin E.
    Hess, Evelyn V.
    Hudson, James I.
    ARTHRITIS AND RHEUMATISM, 2007, 56 (04): : 1336 - 1344
  • [46] A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis
    Wallwork, B
    Coman, W
    Mackay-Sim, A
    Greiff, L
    Cervin, A
    LARYNGOSCOPE, 2006, 116 (02): : 189 - 193
  • [47] Ziprasidone in the acute treatment of mania: A double-blind, placebo-controlled, randomized trial
    Giller, E
    Mandel, FS
    Keck, P
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 229 - 229
  • [48] Acute migraine treatment with droperidol - A randomized, double-blind, placebo-controlled trial
    Silberstein, SD
    Young, WB
    Mendizabal, JE
    Rothrock, JF
    Alam, AS
    NEUROLOGY, 2003, 60 (02) : 315 - 321
  • [49] Randomized, double-blind, placebo-controlled trial of rofecoxib for the acute treatment of migraine
    Tepper, S
    Silberstein, S
    Brandes, J
    Venkatraman, S
    Vrijens, F
    Malbecq, W
    Visser, WH
    Reines, S
    Yuen, E
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 300 - 300
  • [50] RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL OF KETANSERIN IN TREATMENT OF INTERMITTENT CLAUDICATION
    WALDEN, R
    BASS, A
    RABI, I
    ADAR, R
    JOURNAL OF CARDIOVASCULAR SURGERY, 1991, 32 (06): : 737 - 740